Loading...
Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma
Multiple myeloma (MM) is a relapsed and refractory disease, one that highlights the need for developing new molecular therapies for overcoming of drug resistance. Addition of panobinostat, a histone deacetylase (HDAC) inhibitor, to bortezomib and dexamethasone improved progression-free survival (PFS...
Na minha lista:
| Udgivet i: | JCI Insight |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society for Clinical Investigation
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5033869/ https://ncbi.nlm.nih.gov/pubmed/27699258 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.85061 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|